{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:49:15Z","timestamp":1792104555363,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"DOI":"10.1007\/s40744-026-00882-x","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:28:18Z","timestamp":1792103298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Newly Initiated Tofacitinib and Biologic DMARDs in Patients with Rheumatoid Arthritis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4797-3200","authenticated-orcid":false,"given":"Katherine P.","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekar","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-4094","authenticated-orcid":false,"given":"Jinoos","family":"Yazdany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj Sarvode","family":"Mothi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griffith","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Yndestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8351-4626","authenticated-orcid":false,"given":"Milena A.","family":"Gianfrancesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"10055","key":"882_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet"},{"key":"882_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s41927-019-0080-9","volume":"3","author":"W Katchamart","year":"2019","unstructured":"Katchamart W, Narongroeknawin P, Chanapai W, Thaweeratthakul P. Health-related quality of life in patients with rheumatoid arthritis. BMC Rheumatol. 2019;3:34.","journal-title":"BMC Rheumatol."},{"issue":"3","key":"882_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030509","volume":"10","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, Atzeni F, Balsa A, Gossec L, M\u00fcller-Ladner U, Pope J. The key comorbidities in patients with rheumatoid arthritis: a narrative review. J Clin Med. 2021;10(3):509.","journal-title":"J Clin Med"},{"issue":"7","key":"882_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924\u201339.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"882_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.ard.2026.01.023","volume":"85","author":"JS Smolen","year":"2025","unstructured":"Smolen JS, Edwards CJ, Konzett V, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis. 2025;85(6):991\u20131009.","journal-title":"Ann Rheum Dis"},{"issue":"10093","key":"882_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double\u2010blind, head\u2010to\u2010head, randomised controlled trial. Lancet. 2017;390(10093):457\u201368.","journal-title":"Lancet"},{"issue":"25","key":"882_CR7","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377\u201386.","journal-title":"N Engl J Med"},{"issue":"6","key":"882_CR8","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508\u201319.","journal-title":"N Engl J Med"},{"issue":"4","key":"882_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li Z-G, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253\u201361.","journal-title":"Ann Intern Med."},{"issue":"6","key":"882_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495\u2013507.","journal-title":"N Engl J Med"},{"issue":"6","key":"882_CR11","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/art.40803","volume":"71","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Strand V, Tanaka Y, et al. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study. Arthritis Rheumatol. 2019;71(6):878\u201391.","journal-title":"Arthritis Rheumatol"},{"issue":"9865","key":"882_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451\u201360.","journal-title":"Lancet"},{"key":"882_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41746-020-0277-8","volume":"3","author":"AJ Averitt","year":"2020","unstructured":"Averitt AJ, Weng C, Ryan P, Perotte A. Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations. NPJ Digit Med. 2020;3:67.","journal-title":"NPJ Digit Med."},{"issue":"9","key":"882_CR14","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","volume":"158","author":"WA Ray","year":"2003","unstructured":"Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915\u201320.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"882_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/ar3260","volume":"13","author":"SY Kim","year":"2011","unstructured":"Kim SY, Servi A, Polinski JM, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther. 2011;13(1):R32.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"882_CR16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","volume":"168","author":"SR Cole","year":"2008","unstructured":"Cole SR, Hern\u00e1n MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656\u201364.","journal-title":"Am J Epidemiol"},{"issue":"25","key":"882_CR17","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"issue":"3","key":"882_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001781","volume":"7","author":"AK Spencer","year":"2021","unstructured":"Spencer AK, Bandaria J, Leavy MB, et al. Validation of a machine learning approach to estimate Clinical Disease Activity Index scores for rheumatoid arthritis. RMD Open. 2021;7(3):e001781.","journal-title":"RMD Open"},{"issue":"10","key":"882_CR19","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","volume":"81","author":"K Lauper","year":"2022","unstructured":"Lauper K, Iudici M, Mongin D, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the \u201cJAK-pot\u201d collaboration. Ann Rheum Dis. 2022;81(10):1358\u201366.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"882_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40744-022-00523-z","volume":"10","author":"LR Harrold","year":"2023","unstructured":"Harrold LR, Wittstock K, Kelly S, et al. Comparative effectiveness of abatacept vs. tofacitinib in rheumatoid arthritis patients who are CCP. Rheumatol Ther. 2023;10(3):575\u201387.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"882_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001601","volume":"7","author":"S Mori","year":"2021","unstructured":"Mori S, Urata Y, Yoshitama T, Ueki Y. Tofacitinib versus tocilizumab in the treatment of biological-na\u00efve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis. RMD Open. 2021;7(2):e001601.","journal-title":"RMD Open"},{"issue":"1","key":"882_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000742","volume":"5","author":"P Bird","year":"2019","unstructured":"Bird P, Hall S, Nash P, et al. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in phase III randomised clinical trials of tofacitinib. RMD Open. 2019;5(1):e000742.","journal-title":"RMD Open"},{"issue":"1","key":"882_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002103","volume":"8","author":"AH Dikranian","year":"2022","unstructured":"Dikranian AH, Gonzalez-Gay MA, Wellborne F, et al. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open. 2022;8(1):e002103.","journal-title":"RMD Open"},{"issue":"12","key":"882_CR24","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1007\/s10067-022-06307-8","volume":"41","author":"Y Khader","year":"2022","unstructured":"Khader Y, Beran A, Ghazaleh S, Lee-Smith W, Altorok N. Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis. Clin Rheumatol. 2022;41(12):3615\u201327.","journal-title":"Clin Rheumatol"},{"key":"882_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152421","volume":"66","author":"GC McDermott","year":"2024","unstructured":"McDermott GC, DiIorio M, Kawano Y, et al. Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis. Semin Arthritis Rheum. 2024;66:152421.","journal-title":"Semin Arthritis Rheum"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00882-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00882-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00882-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:28:19Z","timestamp":1792103299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00882-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":25,"alternative-id":["882"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00882-x","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"4 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Katherine P. Liao has acted as a consultant for Merck and UCB; Chandrasekar Gopalakrishnan and Suraj Sarvode Mothi are employees and stockholders of OM1 Inc.; Jinoos Yazdany has acted as a consultant for AstraZeneca and UCB; and has received research grants from Aurinia, Bristol Myers Squibb Foundation, Gilead, and AstraZeneca; Genevieve Gauthier, Griffith Bell, Arne Yndestad and Milena Gianfrancesco are employees and stockholders of Pfizer Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered strictly to all relevant legal and regulatory frameworks concerning patient privacy, including the Health Insurance Portability and Accountability Act. No direct patient interaction or primary collection of individual human patient data was conducted. Consequently, informed consent, approval from an Independent Ethics Committee, or Institutional Review Board was not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}